2011 Fiscal Year Final Research Report
Pharmaokinetics of intravitreally injected vascular endothelial growth factor
| Project/Area Number |
21592255
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
OHJI Masahito 滋賀医科大学, 医学部, 教授 (90252650)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAWAMURA Hajime 滋賀医科大学, 医学部, 講師 (50294814)
SAWADA Osamu 滋賀医科大学, 医学部, 助教 (00378465)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | VEGF / VEGF阻害薬 / 薬物動態 / 硝子体注射 / サル |
|---|
| Research Abstract |
We evaluated the pharmacokinetics of intravitreally injected bevacizumab which is widely used as an off-label drug. Intravitreal injection of regular dose of bevacizumab(1. 25mg) inhibited VEGF for 4-6 weeks. Minimum effective dose of bevacizumab to suppress VEGF was 6. 25μg which is 1/200 of the regular dose. The half-life of intravitreally injected bevacizumab was 1. 5 days in a-vitreous eyes while it was 2. 8 days in normal eyes. These findings would be useful information for the safe and effective use of bevacizumab.
|
